Phoslyra generic
Phoslyra is an oral medication manufactured by Fresenius Medical. The active ingredient in this drug is calcium acetate. It was first approved for market use on April 18, 2011. Phoslyra is under the protection of 3 patents.
When will Phoslyra generic be available?
The generic version of Phoslyra is slated for release after February 23, 2030. This date corresponds with the expiry of their last patent. The Phoslyra generic will likely become available after this date.
Phoslyra uses
Phoslyra is primarily used for the reduction of serum phosphorous in patients. Its active element, calcium acetate, plays a vital role in achieving this function.
Phoslyra patent expiration
Phoslyra is protected by three patents, with the last one set to expire on February 23, 2030. This suggests that the Phoslyra generic will not be available until after this date. Below are the details of the patents: